{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:03:34Z","timestamp":1780581814199,"version":"3.54.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012513","name":"CIBER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","award":["CB 2021"],"award-info":[{"award-number":["CB 2021"]}],"id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB21\/13\/00039"],"award-info":[{"award-number":["CB21\/13\/00039"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB21\/13\/00044"],"award-info":[{"award-number":["CB21\/13\/00044"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD20CIII\/00001"],"award-info":[{"award-number":["CD20CIII\/00001"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00657"],"award-info":[{"award-number":["PI17\/00657"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/00903"],"award-info":[{"award-number":["PI17\/00903"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17CIII\/00003"],"award-info":[{"award-number":["PI17CIII\/00003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19CIII\/00009"],"award-info":[{"award-number":["PI19CIII\/00009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00474"],"award-info":[{"award-number":["PI20\/00474"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00507"],"award-info":[{"award-number":["PI20\/00507"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20CIII\/00004"],"award-info":[{"award-number":["PI20CIII\/00004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0017"],"award-info":[{"award-number":["RD16\/0025\/0017"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0025\/0018"],"award-info":[{"award-number":["RD16\/0025\/0018"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16CIII\/0002\/0002"],"award-info":[{"award-number":["RD16CIII\/0002\/0002"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.biopha.2022.113024","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T13:23:56Z","timestamp":1650893036000},"page":"113024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis"],"prefix":"10.1016","volume":"150","author":[{"given":"Daniel","family":"Sep\u00falveda-Crespo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Y\u00e9lamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Honta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Torresano-Felipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Iba\u00f1ez-Samaniego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113024_bib1","unstructured":"World Health Organization, Hepatitis C, Geneva, Switzerland, 2021."},{"issue":"1 Suppl","key":"10.1016\/j.biopha.2022.113024_bib2","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113024_bib3","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J. Hepatol."},{"issue":"7350","key":"10.1016\/j.biopha.2022.113024_bib5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/474S2a","article-title":"Introduction: a smouldering public-health crisis","volume":"474","author":"Gravitz","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2022.113024_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2022.113024_bib7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann. Intern Med"},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir +\/- ribavirin vs. ombitasvir\/paritaprevir\/ritonavir + dasabuvir +\/- ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"Backus","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.biopha.2022.113024_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the united kingdom? epidemiological and modeling insights","volume":"62","author":"Martin","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143836","article-title":"Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs?","volume":"10","author":"Lima","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/liv.14011","article-title":"E.S.G.f.V. Hepatitis, Hepatitis C: Is eradication possible?","volume":"39","author":"Lombardi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.biopha.2022.113024_bib13","article-title":"Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants","volume":"8","author":"Sepulveda-Crespo","year":"2020"},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40265-020-01458-x","article-title":"Strategies targeting the innate immune response for the treatment of hepatitis C virus-associated liver fibrosis","volume":"81","author":"Sepulveda-Crespo","year":"2021","journal-title":"Drugs"},{"issue":"10207","key":"10.1016\/j.biopha.2022.113024_bib15","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","volume":"394","author":"Spearman","year":"2019","journal-title":"Hepat. C., Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.113024_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/liv.14363","article-title":"Micro-elimination of hepatitis C virus","volume":"40","author":"Hollande","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib19","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/jvh.12967","article-title":"Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy","volume":"25","author":"Hayashi","year":"2018","journal-title":"J. Viral Hepat."},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib20","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.01.002","article-title":"Hepatitis C \u201ctrue\u201d late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy","volume":"66","author":"Klag","year":"2017","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113024_bib21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2169\/internalmedicine.9671-17","article-title":"Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection with liver cirrhosis","volume":"57","author":"Uojima","year":"2018","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0000000000002103","article-title":"Study, Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV\/hepatitis C virus coinfected individuals","volume":"33","author":"Berenguer","year":"2019","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib23","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1038\/s41598-017-04931-y","article-title":"Identification of HCV resistant variants against direct acting antivirals in plasma and liver of treatment naive patients","volume":"7","author":"Raj","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/hep.31182","article-title":"Hepatitis C Vaccine: 10 good reasons for continuing","volume":"71","author":"Roingeard","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.biopha.2022.113024_bib25","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MEG.0000000000000964","volume":"29","author":"Dolmazashvili","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40121-018-0228-8","article-title":"Public health considerations among people who inject drugs with HIV\/HCV co-infection: a review","volume":"8","author":"Murdock","year":"2019","journal-title":"Infect. Dis. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12954-019-0346-y","article-title":"HIV\/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination","volume":"16","author":"Leyna","year":"2019","journal-title":"Harm Reduct. J."},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/jvh.12966","article-title":"The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania","volume":"25","author":"Mohamed","year":"2018","journal-title":"J. Viral Hepat."},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1473-3099(18)30469-9","article-title":"Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis","volume":"18","author":"Stone","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib30","doi-asserted-by":"crossref","first-page":"ofv115","DOI":"10.1093\/ofid\/ofv115","article-title":"Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study","volume":"2","author":"Vanhommerig","year":"2015","journal-title":"Open Forum Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Andaluz para el Estudio de las Enfermedades, survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","article-title":"HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study","volume":"18","author":"Neukam","year":"2017","journal-title":"HIV Clin. Trials"},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2022.113024_bib33","article-title":"Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?","volume":"21","author":"Martin","year":"2018","journal-title":"J. Int AIDS Soc."},{"key":"10.1016\/j.biopha.2022.113024_bib34","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fimmu.2018.01315","article-title":"The neutralizing face of hepatitis C virus E2 envelope glycoprotein","volume":"9","author":"Tzarum","year":"2018","journal-title":"Front Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2022.113024_bib35","doi-asserted-by":"crossref","first-page":"9128","DOI":"10.1128\/JVI.01194-15","article-title":"Immunoglobulin with high-titer in vitro cross-neutralizing hepatitis C virus antibodies passively protects chimpanzees from homologous, but not heterologous, challenge","volume":"89","author":"Bukh","year":"2015","journal-title":"J. Virol."},{"issue":"254","key":"10.1016\/j.biopha.2022.113024_bib36","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/hep.24171","article-title":"In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus","volume":"53","author":"Meuleman","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat. Med"},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib39","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/hep.27013","article-title":"Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses","volume":"59","author":"Osburn","year":"2014","journal-title":"Hepatology"},{"issue":"27","key":"10.1016\/j.biopha.2022.113024_bib40","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jir835","article-title":"Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion","volume":"205","author":"Raghuraman","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-020-00669-4","article-title":"Hepatitis C virus vaccine design: focus on the humoral immune response","volume":"27","author":"Sepulveda-Crespo","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"7500","key":"10.1016\/j.biopha.2022.113024_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nature"},{"issue":"6162","key":"10.1016\/j.biopha.2022.113024_bib44","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.biopha.2022.113024_bib45","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib46","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036962","article-title":"Antibody Responses in Hepatitis C Infection","volume":"11","author":"Law","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"9","key":"10.1016\/j.biopha.2022.113024_bib47","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1086\/651599","article-title":"Prospective follow-up of patients with acute hepatitis C virus infection in Brazil","volume":"50","author":"Lewis-Ximenez","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2022.113024_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2334-11-15","article-title":"Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil","volume":"11","author":"Strasak","year":"2011","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib49","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/hiv.12602","article-title":"H.I.V.C.S. the Swiss, Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men","volume":"19","author":"Aebi-Popp","year":"2018","journal-title":"HIV Med."},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.patbio.2006.01.005","article-title":"[Rapid seroreversion following spontaneous recovery of acute hepatitis C in an HIV infected patient]","volume":"54","author":"Vaghefi","year":"2006","journal-title":"Pathol. Biol. (Paris)"},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib51","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/ciu695","article-title":"Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men","volume":"59","author":"Vanhommerig","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2022.113024_bib52","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/598993","article-title":"Seroreversion of hepatitis C virus (HCV) antibodies in an HIV-infected patient despite continuous HCV replication","volume":"48","author":"Garcia-Costa","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib53","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.1038\/s41598-019-48592-5","article-title":"Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV\/HCV-coinfected patients who achieved SVR","volume":"9","author":"Vigon","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2008.10.013","article-title":"Structural properties of the ectodomain of hepatitis C virus E2 envelope protein","volume":"139","author":"Rodriguez-Rodriguez","year":"2009","journal-title":"Virus Res."},{"issue":"7","key":"10.1016\/j.biopha.2022.113024_bib55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib56","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.0711044105","article-title":"Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization","volume":"105","author":"Scheel","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.biopha.2022.113024_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","article-title":"Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs","volume":"49","author":"Gottwein","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib58","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","article-title":"Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a\/2a (S52\/JFH1) viruses","volume":"133","author":"Gottwein","year":"2007","journal-title":"Gastroenterology"},{"issue":"5734","key":"10.1016\/j.biopha.2022.113024_bib59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1126\/science.1114016","article-title":"Complete replication of hepatitis C virus in cell culture","volume":"309","author":"Lindenbach","year":"2005","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.biopha.2022.113024_bib60","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1073\/pnas.0504877103","article-title":"Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras","volume":"103","author":"Pietschmann","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.gastrohep.2012.11.005","article-title":"The molecular biology of hepatitis C virus","volume":"36","author":"Koutsoudakis","year":"2013","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2022.113024_bib62","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3389\/fimmu.2018.01703","article-title":"Defining breadth of hepatitis C virus neutralization","volume":"9","author":"Kinchen","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113024_bib63","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2021.04.045","article-title":"Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens","volume":"75","author":"Shah","year":"2021","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2022.113024_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92872","article-title":"Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance","volume":"2","author":"Bailey","year":"2017","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.biopha.2022.113024_bib66","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14760584.2019.1690458","article-title":"Strategies for inducing effective neutralizing antibody responses against HIV-1","volume":"18","author":"Del Moral-Sanchez","year":"2019","journal-title":"Expert Rev. Vaccin."},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14760584.2017.1299576","article-title":"Strategies to induce broadly protective antibody responses to viral glycoproteins","volume":"16","author":"Krammer","year":"2017","journal-title":"Expert Rev. Vaccin."},{"issue":"8","key":"10.1016\/j.biopha.2022.113024_bib68","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Justice, Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"Lo","year":"2014","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib70","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-018-9896-4","article-title":"A changing paradigm: management and treatment of the HCV\/HIV-co-infected patient","volume":"12","author":"Abutaleb","year":"2018","journal-title":"Hepatol. Int."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2050-7771-1-8","article-title":"Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms","volume":"1","author":"Coker","year":"2013","journal-title":"Biomark. Res."},{"issue":"5","key":"10.1016\/j.biopha.2022.113024_bib73","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood-2005-11-013383","article-title":"Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection","volume":"108","author":"Titanji","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib74","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ni1302","article-title":"Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells","volume":"7","author":"Qiao","year":"2006","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113024_bib75","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/ni.1753","article-title":"HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits","volume":"10","author":"Xu","year":"2009","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113024_bib76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","article-title":"Structural insights on the role of antibodies in HIV-1 vaccine and therapy","volume":"156","author":"West","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2022.113024_bib77","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.4049\/jimmunol.177.6.3728","article-title":"A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation","volume":"177","author":"Fecteau","year":"2006","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113024_bib78","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.4049\/jimmunol.178.12.8212","article-title":"Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease","volume":"178","author":"Hart","year":"2007","journal-title":"J. Immunol."},{"issue":"7350","key":"10.1016\/j.biopha.2022.113024_bib79","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nature10168","article-title":"A genetically humanized mouse model for hepatitis C virus infection","volume":"474","author":"Dorner","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2022.113024_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.biopha.2022.113024_bib81","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1053\/j.gastro.2009.02.080","article-title":"Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus","volume":"136","author":"Dowd","year":"2009","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.biopha.2022.113024_bib82","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","article-title":"Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection","volume":"79","author":"Lavillette","year":"2005","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/j.biopha.2022.113024_bib83","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.biopha.2022.113024_bib84","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/liv.14762","article-title":"HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men","volume":"41","author":"Adu","year":"2021","journal-title":"Liver Int."},{"issue":"17","key":"10.1016\/j.biopha.2022.113024_bib85","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","article-title":"Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men","volume":"29","author":"Hagan","year":"2015","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.biopha.2022.113024_bib86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"N.s. group, HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2017","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113024_bib87","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.04.030","article-title":"Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates","volume":"443","author":"Lu","year":"2013","journal-title":"Virology"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222004139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:53:56Z","timestamp":1780487636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222004139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":87,"alternative-id":["S0753332222004139"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113024","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113024"}}